Chasing China

How Nan Fung Life Sciences plans to invest its Pivotal China fund

While Nan Fung Life Sciences had planned to establish a longer track record in biotech investments before launching its first China-focused fund, the group accelerated its plans to capitalize on the growing Chinese biotech industry. On Thursday, Nan Fung subsidiary Pivotal China announced its inaugural $150 million fund,

Read the full 480 word article

User Sign In